Diversion Control Division, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

September

Salman Akbar, M.D.; Decision and Order (PDF) (September 20, 2021)

Humberto A. Florian, M.D.; Decision and Order (September 20, 2021)

Steven P. French, M.D.; Decision and Order (September 20, 2021)

Lisa M. Jones, N.P.; Dismissal of Proceedings (September 20, 2021)

Final Rule: Addition of the United States Space Force as a Registration Waiver and Registration Fee Exempt Military Entity (September 17, 2021)

Cambridge Isotope Laboratories (September 15, 2021)

Amethyst Exploration, LLC (September 13, 2021)

Eli-Elsohly Laboratories (September 13, 2021)

Cayman Chemical Company (September 13, 2021)

Aurobindo Pharma USA, Inc. (September 13, 2021)

Uvienome Linda Sakor, N.P.; Decision and Order (September 7, 2021)

Lora L. Thaxton, M.D.; Decision and Order (September 7, 2021)

Proposed Rule: Placement of Methiopropamine in Schedule I (September 2, 2021)

Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021 (September 2, 2021)


August

Chemtos, LLC (August 27, 2021)

Cambrex Charles City (August 27, 2021)

Benuvia Therapeutics Inc. (August 25, 2021)

Absolute Standards, Inc. (August 25, 2021)

Cedarburg Pharmaceuticals (August 25, 2021)

Johnson Matthey Inc. (August 25, 2021)

Galephar Pharmaceutical Research Inc. (August 19, 2021)

Chattem Chemicals, Inc. (August 19, 2021)

Catalent CTS, LLC (August 13, 2021)

Final Rule: Placement of 4,4'-DMAR in Schedule I (August 12, 2021)

PA Options for Wellness, Inc. (August 12, 2021)

Epic Pharma, LLC (August 12, 2021)

Globyz Pharma, LLC (August 12, 2021)

Cambrex High Point, Inc. (August 12, 2021)

MP Pharma Services (August 12, 2021)

Curium US, LLC (August 12, 2021)

Proposed Rule: Placement of Mesocarb in Schedule I (August 11, 2021)

Cambrex High Point, Inc. (August 5, 2021)

Purisys, LLC (August 3, 2021)

Cerilliant Corporation (August 3, 2021)

AMRI Rensselaer, Inc. (August 2, 2021)


July

AMPAC Fine Chemicals, LLC (July 29, 2021)

Nusachi Labs, LLC (July 29, 2021)

Cerilliant Corporation (July 29, 2021)

Purisys, LLC (July 29, 2021)

Care Point Pharmacy, Inc.; Decision and Order (July 28, 2021)

Creekbend Community Pharmacy; Decision and Order (July 28, 2021)

William Ralph Kinkaid, M.D.; Decision and Order (July 28, 2021)

Erica N. Grant, M.D.; Decision and Order (July 28, 2021)

Novitium Pharma, LLC (July 27, 2021)

Catalent Pharma Solutions, LLC (July 27, 2021)

Arizona Department of Corrections (July 23, 2021)

Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (July 22, 2021)

Proposed Rule: Placement of Amineptine in Schedule I (July 22, 2021)

Direct Final Rule: Clarification Regarding the Supplier's DEA Registration Number on the Single-Sheet DEA Form 222 (July 20, 2021)

Proposed Rule: Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4'-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4'-Chloro-alpha-pyrrolidinovalerophenone in Schedule I (July 16, 2021)

Extension of Temporary Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4'-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4'-Chloro-alpha-pyrrolidinovalerophenone in Schedule I of the Controlled Substances Act (July 16, 2021)

Alcami Carolinas Corporation (July 8, 2021)

Aspen API, Inc. (July 8, 2021)

30-Day Notice: Exempt Chemical Preparations Application (July 6, 2021)

Spring Valley Family Pharmacy; Decision and Order (July 2, 2021)

Keith A. Jenkins, N.P.; Decision and Order (July 2, 2021)

United States Pharmacopeial Convention (July 2, 2021)


June

Final Rule: Registration Requirements for Narcotic Treatment Programs With Mobile Components (PDF) (June 28, 2021)

Chemic Laboratories (June 28, 2021)

AMRI Rensselaer, Inc. (June 28, 2021)

Robert Wayne Locklear, M.D.; Decision and Order (PDF) (June 25, 2021)

Carol Hippenmeyer, M.D.; Decision and Order (PDF) (June 25, 2021)

Final Rule: Placement of para-Methoxymethamphetamine (PMMA) in Schedule I (June 25, 2021)

Cambrex Charles City (June 24, 2021)

Annac Medical Center LC (June 24, 2021)

Purisys, LLC (June 23, 2021)

Final Rule: Specific Listing for 4F-MDMB-BINACA, a Currently Controlled Schedule I Substance (June 22, 2021)

Organix Inc. (June 17, 2021)

AMPAC Fine Chemicals Virginia, LLC (June 17, 2021)

Johnny C. Benjamin, Jr., M.D.; Decision and Order (June 17, 2021)

Tareq A. Khedir Al-Tiae, M.D.; Decision and Order (June 17, 2021)

Xcelience (June 17, 2021)

Andersonbrecon Inc. DBA PCI of Illinois (June 17, 2021)

Final Rule: Placement of N-Ethylpentylone in Schedule I (June 14, 2021)

Usona Institute (June 14, 2021)

Fisher Clinical Services, Inc. (June 14, 2021)

Adiramedica, LLC (June 11, 2021)

Maridose, LLC (June 10, 2021)

Cambrex Charles City (June 10, 2021)

Fisher Clinical Services, Inc. (June 10, 2021)

National Center for Natural Products Research (June 10, 2021)

Final Rule: Placement of Oliceridine in Schedule II (June 10, 2021)

Final Rule: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA, and 5F-CUMYL-P7AICA in Schedule I (June 10, 2021)

Jennifer L. St. Croix, M.D.; Order Denying Motion To Stay (June 8, 2021)

Designation of 3,4-MDP-2-P Methyl Glycidate (PMK Glycidate), 3,4-MDP-2-P Methyl Glycidic Acid (PMK Glycidic Acid), and Alpha-Phenylacetoacetamide (APAA) as List I Chemicals; Correction (June 7, 2021)

Final Rule: Placement of Remimazolam in Schedule IV (June 2, 2021)


May

Purisys, LLC (May 26, 2021)

Almac Clinical Services Incorp. (ACSI) (May 26, 2021)

American Radiolabeled Chem (May 25, 2021)

SpecGX, LLC (May 25, 2021)

Final Rule: Placement of Lasmiditan in Schedule V (May 24, 2021)

SPECGX LLC (May 18, 2021)

Experic LLC (May 18, 2021)

Lipomed (May 18, 2021)

Unither Manufacturing LLC (May 18, 2021)

Patheon API Manufacturing, Inc. (May 12, 2021)

Rosa A. Fuentes, M.D.; Decision and Order (May 11, 2021)

Final Rule: Designation of 3,4-MDP-2-P methyl glycidate (PMK glycidate), 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid), and alpha-phenylacetoacetamide (APAA) as List I Chemicals (May 10, 2021)

Interim Final Rule: Placement of Serdexmethylphenidate in Schedule IV (May 7, 2021)

Indian Flower LLC (May 7, 2021)

Green Rush Organic Farms Inc. (May 7, 2021)

Melanie Baker, N.P.; Decision and Order (May 5, 2021)

Michele L. Martinho, M.D.; Decision and Order (May 5, 2021)

Emmanuel A. Ayodele, M.D.; Decision and Order (May 5, 2021)

Final Rule: Placement of Four Specific Fentanyl-Related Substances in Schedule I (May 4, 2021)

Cargill, Incorporated (May 4, 2021)

VHG Labs DBA LGC Standards (May 4, 2021)

Wildlife Laboratories, LLC (May 4, 2021)


April

Final Rule: Placement of 10 Specific Fentanyl-Related Substances in Schedule I (April 27, 2021)

60-Day Notice: New Proposed Collection Exempt Chemical Preparations Application (April 26, 2021)

Rhodes Technologies (April 26, 2021)

Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (April 23, 2021)

Rhodes Technologies (April 23, 2021)

Cardinal Health (April 23, 2021)

Lipomed (April 23, 2021)

Research Triangle Institute (April 21, 2021)

Mark A. Wimbley, M.D.; Decision and Order (PDF) (April 21, 2021)

Michael Jones, M.D.; Decision and Order (April 21, 2021)

Javaid A. Perwaiz, M.D.; Decision and Order (April 21, 2021)

Research Triangle Institute (April 21, 2021)

Scottsdale Research Institute (April 21, 2021)

The Pharmacy Place; Order (PDF) (April 21, 2021)

Final Rule: Removal of Samidorphan From Control (April 19, 2021)

Jennifer L. St. Croix, M.D.; Decision and Order (PDF) (April 12, 2021)

Royal Emerald Pharmaceuticals (April 5, 2021)

Brenton D. Goodman, M.D.; Decision and Order (April 2, 2021)

Kendrick E. Duldulao, M.D.; Decision and Order (April 2, 2021)

ThinkPur, LLC (April 1, 2021)

Sharp Clinical Services, Inc. (April 1, 2021)

Emergency Disaster Relief
Search for Year Round Pharmaceutical Disposal Locations.
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility